Mortality risk of COVID-19 in elderly males with comorbidities : a multi-country study
The COVID-19 pandemic causes severe morbidity and mortality. This multi-country study aimed to explore risk factors that drive mortality in COVID-19 patients who received neither dexamethasone nor remdesivir. We analyzed a cohort of 568 survivors and 507 non-survivors from China, European regions, and North America. Elderly males ≥70 years accounted for only 25% of survivors, but this rate was significantly higher in non-survivors from China (55%), European regions (63%), and North America (47%). Compared with survivors, non-survivors had more incidences of comorbidities such as cerebrovascular disease and chronic obstructive pulmonary disease (COPD, p-values<0.05). Survival analyses revealed age, male gender, shortness of breath, cerebrovascular disease, and COPD as mortality-associated factors. Survival time from symptom onset was significantly shorter in elderly versus young patients (median: 29 versus 62 days), males versus females (median: 46 versus 59 days), and patients with versus without comorbidities (mean: 41 versus 61 days). Mortality risk was higher in elderly males with comorbidities than in young females without comorbidities (p-value<0.01). Elderly male survivors with comorbidities also had longer hospital stays than other survivors (25 versus 18.5 days, p-value<0.01). Overall, the high mortality risk in elderly males with COVID-19-associated comorbidities supports early prevention and critical care for elderly populations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Aging - 13(2020), 1 vom: 31. Dez., Seite 27-60 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Guangdi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 28.01.2021 Date Revised 23.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.18632/aging.202456 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320345378 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320345378 | ||
| 003 | DE-627 | ||
| 005 | 20231225173358.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18632/aging.202456 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1067.xml |
| 035 | |a (DE-627)NLM320345378 | ||
| 035 | |a (NLM)33472167 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Guangdi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mortality risk of COVID-19 in elderly males with comorbidities |b a multi-country study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.01.2021 | ||
| 500 | |a Date Revised 23.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The COVID-19 pandemic causes severe morbidity and mortality. This multi-country study aimed to explore risk factors that drive mortality in COVID-19 patients who received neither dexamethasone nor remdesivir. We analyzed a cohort of 568 survivors and 507 non-survivors from China, European regions, and North America. Elderly males ≥70 years accounted for only 25% of survivors, but this rate was significantly higher in non-survivors from China (55%), European regions (63%), and North America (47%). Compared with survivors, non-survivors had more incidences of comorbidities such as cerebrovascular disease and chronic obstructive pulmonary disease (COPD, p-values<0.05). Survival analyses revealed age, male gender, shortness of breath, cerebrovascular disease, and COPD as mortality-associated factors. Survival time from symptom onset was significantly shorter in elderly versus young patients (median: 29 versus 62 days), males versus females (median: 46 versus 59 days), and patients with versus without comorbidities (mean: 41 versus 61 days). Mortality risk was higher in elderly males with comorbidities than in young females without comorbidities (p-value<0.01). Elderly male survivors with comorbidities also had longer hospital stays than other survivors (25 versus 18.5 days, p-value<0.01). Overall, the high mortality risk in elderly males with COVID-19-associated comorbidities supports early prevention and critical care for elderly populations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a comorbidities | |
| 650 | 4 | |a mortality | |
| 650 | 4 | |a risk factors | |
| 700 | 1 | |a Liu, Yacong |e verfasserin |4 aut | |
| 700 | 1 | |a Jing, Xixi |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yali |e verfasserin |4 aut | |
| 700 | 1 | |a Miao, Miao |e verfasserin |4 aut | |
| 700 | 1 | |a Tao, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Zhiguo |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Yuanlin |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Yaxiong |e verfasserin |4 aut | |
| 700 | 1 | |a Lei, Jianhua |e verfasserin |4 aut | |
| 700 | 1 | |a Gong, Guozhong |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Hao, Yuantao |e verfasserin |4 aut | |
| 700 | 1 | |a Faria, Nuno Rodrigues |e verfasserin |4 aut | |
| 700 | 1 | |a Clercq, Erik De |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Min |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Aging |d 2008 |g 13(2020), 1 vom: 31. Dez., Seite 27-60 |w (DE-627)NLM192249398 |x 1945-4589 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2020 |g number:1 |g day:31 |g month:12 |g pages:27-60 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18632/aging.202456 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2020 |e 1 |b 31 |c 12 |h 27-60 | ||